Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RDY 
Dr. Reddy’s Laboratories Ltd ADR (RDY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RDY (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.3
1 Year Target Price $15.3
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.78% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.99B USD | Price to earnings Ratio 18.09 | 1Y Target Price 15.3 |
Price to earnings Ratio 18.09 | 1Y Target Price 15.3 | ||
Volume (30-day avg) 4 | Beta 0.31 | 52 Weeks Range 12.20 - 16.76 | Updated Date 08/15/2025 |
52 Weeks Range 12.20 - 16.76 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 0.65% | Basic EPS (TTM) 0.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-23 | When - | Estimate 0.21 | Actual 0.2 |
Profitability
Profit Margin 16.99% | Operating Margin (TTM) 20.5% |
Management Effectiveness
Return on Assets (TTM) 9.71% | Return on Equity (TTM) 17.71% |
Valuation
Trailing PE 18.09 | Forward PE 18.05 | Enterprise Value 11779438825 | Price to Sales(TTM) 0.04 |
Enterprise Value 11779438825 | Price to Sales(TTM) 0.04 | ||
Enterprise Value to Revenue 3.08 | Enterprise Value to EBITDA 10.5 | Shares Outstanding 832371008 | Shares Floating 595103539 |
Shares Outstanding 832371008 | Shares Floating 595103539 | ||
Percent Insiders - | Percent Institutions 14.64 |
Upturn AI SWOT
Dr. Reddy’s Laboratories Ltd ADR
Company Overview
History and Background
Dr. Reddy's Laboratories Ltd was founded in 1984 by Dr. K. Anji Reddy in Hyderabad, India. Initially, it focused on manufacturing active pharmaceutical ingredients (APIs). Over time, it evolved into a fully integrated pharmaceutical company with a global presence, expanding into generics, branded formulations, and biosimilars.
Core Business Areas
- Generics: Development, manufacturing, and marketing of generic pharmaceutical products across various therapeutic areas and dosage forms. Focus on US and European markets.
- Pharmaceutical Services and Active Ingredients (PSAI): Manufacturing and supply of APIs to generic and innovator companies globally. Services also include custom manufacturing and research.
- Proprietary Products: Research, development, and commercialization of differentiated formulations, biosimilars, and novel drugs. Focus on dermatology and oncology.
Leadership and Structure
The company is led by a board of directors, with key executives including the CEO and CFO. The organizational structure includes various functional departments such as R&D, manufacturing, sales and marketing, and finance, operating across different geographies.
Top Products and Market Share
Key Offerings
- Generic Pharmaceuticals (e.g., Omeprazole, Atorvastatin): Dr. Reddy's has a wide portfolio of generic drugs, particularly in areas like cardiovascular diseases, gastrointestinal disorders, and pain management. Market share varies by specific product and region. Competitors include Teva, Mylan, and Sun Pharma.
- Biosimilars (e.g., Rituximab biosimilar): Dr. Reddy's is actively developing and launching biosimilars, which are highly similar versions of originator biologic drugs. Competitors include Sandoz, Biocon, and Pfizer.
- Specialty Pharmaceuticals: These are complex formulations and therapies in niche markets like dermatology and cancer. It accounts for a significant portion of Dr. Reddyu2019s revenue. Competitors include Roche, Johnson & Johnson and other companies with portfolios of specialty medications
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, strict regulatory requirements, and increasing pressure to reduce healthcare costs. The generics market is driven by patent expirations of blockbuster drugs, while the biosimilars market is growing rapidly as a more affordable alternative to biologics.
Positioning
Dr. Reddy's is a mid-sized global pharmaceutical company with a strong presence in generics and a growing focus on biosimilars and proprietary products. It leverages its manufacturing capabilities and R&D expertise to compete in the market.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. Dr. Reddy's is positioned to capture a share of this market through its generics, biosimilars, and proprietary products, focusing on key geographies like the US and emerging markets. Generics are about $400 Billion and Dr. Reddy is well positioned to capture a part of it.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Global manufacturing footprint
- Diversified product portfolio
- Established presence in key markets
- Focus on innovation and specialty products
Weaknesses
- Reliance on generic drug pricing
- Exposure to regulatory risks
- Competition from larger pharmaceutical companies
- Potential delays in product approvals
- Vulnerability to currency fluctuations
Opportunities
- Expansion into new markets
- Development of novel therapies
- Strategic acquisitions and partnerships
- Increasing demand for biosimilars
- Growth in emerging markets
Threats
- Intense competition in the generics market
- Pricing pressures from payers
- Changes in regulatory policies
- Patent challenges and litigation
- Economic downturns
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- RDY.AX
Competitive Landscape
Dr. Reddy's competes with larger pharmaceutical companies in the generics and biosimilars markets. Its competitive advantages include its manufacturing capabilities, R&D expertise, and focus on niche products.
Major Acquisitions
OctoPlus N.V.
- Year: 2010
- Acquisition Price (USD millions): 37.6
- Strategic Rationale: Acquisition enhanced Dr. Reddy's drug delivery capabilities and provided access to microparticle technology.
Growth Trajectory and Initiatives
Historical Growth: Dr. Reddy's has experienced growth through acquisitions, product launches, and expansion into new markets.
Future Projections: Analysts project moderate growth for Dr. Reddy's, driven by its focus on biosimilars and proprietary products. Projections vary based on market conditions and company performance.
Recent Initiatives: Recent initiatives include strategic partnerships, investments in R&D, and expansion into new therapeutic areas.
Summary
Dr. Reddy's is a moderately strong pharmaceutical company with a diverse product portfolio and global presence. Its focus on biosimilars and proprietary products positions it for future growth. However, it faces challenges from competition in the generics market and regulatory pressures. Strategic acquisitions and partnerships will be critical for continued success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry databases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered as financial advice. Investment decisions should be based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dr. Reddy’s Laboratories Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2001-04-11 | CEO & Member of the Management Council Mr. Erez Israeli M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 27811 | Website https://www.drreddys.com |
Full time employees 27811 | Website https://www.drreddys.com | ||
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.